Gilead Sciences (GILD) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gilead Sciences (GILD) has outperformed GSK (GSK) over the past year, gaining 24.4% versus a gain of 8.1%. Over five years, GILD leads with a +117.1% price change compared with +20.5% for GSK. Gilead Sciences is the larger company by market cap ($182.40 billion vs $93.24 billion), about 2.0 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 14.9x for Gilead Sciences). Gilead Sciences offers the higher dividend yield (2.19% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | GSK |
|---|---|---|
| Share price | $147.10 | $46.54 |
| Market cap | $182.40B | $93.24B |
| 1-day change | +0.17% | -1.02% |
| YTD return | +19.85% | -4.12% |
| 1-year return | +24.40% | +8.09% |
| 5-year return | +117.14% | +20.53% |
| P/E ratio (TTM) | — | 14.68 |
| Forward P/E | 14.87 | 9.42 |
| EPS (TTM) | $-2.65 | $3.17 |
| Dividend yield | 2.19% | 1.46% |
| Annual dividend | $3.22 | $0.68 |
| Revenue (latest FY) | $29.44B | — |
| Revenue growth (YoY) | +2.40% | — |
| Net income (latest FY) | $8.51B | — |
| Gross margin | 78.83% | — |
| Operating margin | 34.04% | — |
| Net margin | 28.90% | — |
| 52-week high | $157.29 | $61.70 |
| 52-week low | $114.02 | $42.85 |
| Distance from 52-week high | -6.48% | -24.57% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +8.27% | +27.48% |
| Average volume | 6.01M | 3.77M |
| Shares outstanding | 1.24B | 2.00B |
| Employees | 17,000 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GILD has outperformed GSK by 16.3 percentage points over the past year.
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
GILD vs GSK FAQ
Which is bigger, Gilead Sciences or GSK?
Gilead Sciences (GILD) is larger, with a market capitalization of $182.40B compared with $93.24B for GSK (GSK).
Which stock has performed better over the past year, GILD or GSK?
GILD returned +24.40% over the past 12 months, compared with +8.09% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or GSK?
Gilead Sciences has the higher yield at 2.19%, compared with 1.46% for GSK.
Are Gilead Sciences and GSK in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Gilead Sciences and Biotechnology: Pharmaceutical Preparations for GSK.